CHAOSBOLD: Identification and Dynamics With Cerebral Functional Magnetic Resonance Imaging

Sponsor
Assistance Publique - Hôpitaux de Paris (Other)
Overall Status
Completed
CT.gov ID
NCT01331070
Collaborator
(none)
40
1
2
24
1.7

Study Details

Study Description

Brief Summary

Chronic obstructive pulmonary disease (COPD) is a chronicle inflammatory disease with a non reversible diminution of the airway flow. COPD is caused most commonly from tobacco smoking, which triggers an abnormal inflammatory response in the lung. Worldwide, COPD ranked as the sixth leading cause of death in 1990. It is projected to be the fourth leading cause of death worldwide by 2030 due to an increase in smoking rates and demographic changes in many countries. COPD is responsible for 16000 deaths per year in France, 100 000 hospitalizations per year and the health care expenditure of COPD in France is 3.5 billion of Euros. Classical markers of the disease severity, the forced expiratory volume in one second, poorly correlates with dyspnea and prognosis. Therefore, many studies focused on the control of breathing in an attempt to understand the pathophysiological mechanisms involved in the progression of the disease. Breathing control is enhanced in patients with COPD due to the progressive failure of respiratory muscles (airflow obstruction, static and dynamic hyperinflation, positive intrinsic end expiratory pressure), the ventilation/ perfusion ratio abnormalities leading to the loss of the gaz exchange efficiency. Inspiratory command depends on the medulla automatic pathway and the voluntary corticospinal command. Indirect method of breathing control estimation suggested in COPD patients an increased excitability of neurons involved in the voluntary diaphragm activation and a reduced cortical reserve. This may represent an increase risk factor for acute respiratory failure. Until now, no study reported the central breathing control with cerebral fMRI in COPD patients.

Condition or Disease Intervention/Treatment Phase
  • Other: cerebral fMRI
  • Other: cerebral fMRI
N/A

Detailed Description

Chronic obstructive pulmonary disease (COPD) is a chronicle inflammatory disease with a non reversible diminution of the airway flow. COPD is caused most commonly from tobacco smoking, which triggers an abnormal inflammatory response in the lung. Worldwide, COPD ranked as the sixth leading cause of death in 1990. It is projected to be the fourth leading cause of death worldwide by 2030 due to an increase in smoking rates and demographic changes in many countries. COPD is responsible for 16000 deaths per year in France, 100 000 hospitalizations per year and the health care expenditure of COPD in France is 3.5 billion of Euros. Classical markers of the disease severity, the forced expiratory volume in one second, poorly correlates with dyspnea and prognosis. Therefore, many studies focused on the control of breathing in an attempt to understand the pathophysiological mechanisms involved in the progression of the disease. Breathing control is enhanced in patients with COPD due to the progressive failure of respiratory muscles (airflow obstruction, static and dynamic hyperinflation, positive intrinsic end expiratory pressure), the ventilation/ perfusion ratio abnormalities leading to the loss of the gaz exchange efficiency. Inspiratory command depends on the medulla automatic pathway and the voluntary corticospinal command. Indirect method of breathing control estimation suggested in COPD patients an increased excitability of neurons involved in the voluntary diaphragm activation and a reduced cortical reserve. This may represent an increase risk factor for acute respiratory failure. Until now, no study reported the central breathing control with cerebral fMRI in COPD patients. This pilot study also aims in estimating if the absence or diminution of the cortical reserve is a marker of disease severity. In addition correlations will be performed between activated neuronal signals with fMRI and ventilatory flow output recordings (chaotic analysis).

Study Design

Study Type:
Interventional
Actual Enrollment :
40 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Central Control of Breathing in Patients With Chronic Obstructive Pulmonary Disease: Identification and Dynamics With Cerebral Functional Magnetic Resonance Imaging
Study Start Date :
Mar 1, 2011
Actual Primary Completion Date :
Mar 1, 2012
Actual Study Completion Date :
Mar 1, 2013

Arms and Interventions

Arm Intervention/Treatment
Experimental: PATIENT

Patients, half with moderate (GOLD II) and half with severe (GOLD III) COPD

Other: cerebral fMRI
the central breathing control with cerebral fMRI in COPD patients
Other Names:
  • the central breathing control with cerebral fMRI
  • Other: Accepts Healthy Volunteers

    Control arm with the same intervention

    Other: cerebral fMRI
    the central breathing control with cerebral fMRI in Accepts Healthy Volunteers
    Other Names:
  • the central breathing control with cerebral fMRI
  • Outcome Measures

    Primary Outcome Measures

    1. Central ventilatory control [1 month]

      Evaluation of the central ventilatory control at the patients COPD during the application of an inspiratory resistance.

    Secondary Outcome Measures

    1. Evaluation of the neuronal activation [1 month]

      Evaluation of the neuronal activation bulbo-pontique and corticospinal during the application of an inspiratory resistance.

    2. Chaotic analysis [1 month]

      The correlations will be performed between activated neuronal signals with fMRI and ventilatory flow output recordings (chaotic analysis).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    INCLUSION CRITERIA for Patient:
    • Informed patients with written consent,

    • More than eighteen years old,

    • Patients having a social insurance

    • A previous medical examination

    • Patients, half with moderate (GOLD II) and half with severe (GOLD III) COPD will be included. These patients will be clinically in a steady state situation for at least one month (no acute exacerbation). GOLD grading of COPD patients will be performed according to the American Thoracic Society.

    EXCLUSION CRITERIA for patient:
    • Long-term oxygen therapy

    • Previous cerebral vascular accident

    • Central neurological disease (tumor, Parkinson, etc.)

    • Nobody benefiting from a particular protection: pregnant woman, minor person, major person under guardianship and under guardianship, the persons hospitalized without their consent and protected by the law, or the private persons of freedom.

    • Contraindication in the functional intellectual MRI:

    • Port of a biomedical device like cardiac simulator

    • Cardiac defibrillator

    • Insulin pump or neurostimulating,

    • Claustrophobia,

    • Impossibility to remain lengthened

    • Presence of cerebral vascular clips, metallic foreign body intra-ocular, not compatible cardiac valve

    • Pregnancy

    INCLUSION CRITERIA for Healthy Volunteers:
    • Informed healthy volunteer with written consent,

    • More than eighteen years old,

    • Healthy volunteer having a social insurance

    • A previous medical examination

    • Non-smoker

    • Non pathology and medicinal treatment

    EXCLUSION CRITERIA for healthy volunteers:
    • Nobody benefiting from a particular protection: pregnant woman, minor person, major person under guardianship and under guardianship, the persons hospitalized without their consent and protected by the law, or the private persons of freedom.

    • Contraindication in the functional intellectual MRI:

    • Port of a biomedical device like cardiac simulator

    • Cardiac defibrillator

    • Insulin pump or neurostimulating,

    • Claustrophobia,

    • Impossibility to remain lengthened

    • Presence of cerebral vascular clips, metallic foreign body intra-ocular, not compatible cardiac valve

    • Pregnancy

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hôpital Bichat Paris France 75018

    Sponsors and Collaborators

    • Assistance Publique - Hôpitaux de Paris

    Investigators

    • Principal Investigator: Laurence MANGIN, MD, Assistance Publique - Hôpitaux de Paris

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Assistance Publique - Hôpitaux de Paris
    ClinicalTrials.gov Identifier:
    NCT01331070
    Other Study ID Numbers:
    • P100136
    • AOM10010
    First Posted:
    Apr 7, 2011
    Last Update Posted:
    Aug 14, 2013
    Last Verified:
    Aug 1, 2013
    Keywords provided by Assistance Publique - Hôpitaux de Paris
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 14, 2013